Nucleix, Ltd. – Trademark Portfolio
Entity Type: 03
Nucleix, Ltd. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 5 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include NUCLEIX and EPICHECK. The owner is based in Tel-Aviv.
27 HaBarzel St.
Tel-Aviv 69710 , IL
Showing of trademarks Trademarks
Trademark Classifications
Nucleix, Ltd.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Nucleix, Ltd. have?
Nucleix, Ltd. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does Nucleix, Ltd. file in?
Nucleix, Ltd. files trademarks across 5 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Nucleix, Ltd.'s most well-known trademarks?
Nucleix, Ltd.'s registered trademark portfolio includes well-known marks such as NUCLEIX and EPICHECK. These are among 2 currently registered trademarks in the portfolio.
What is Nucleix, Ltd.'s trademark registration success rate?
Nucleix, Ltd. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.